Globus Medical stock rises on EU approval for imaging system

Globus Medical (NYSE:GMED) shares experienced a 1% increase in after-hours trading on Thursday after the company announced that its Excelsius3D imaging system received CE mark approval for commercial sale in the European Union and United Kingdom. The Excelsius3D is a mobile imaging platform that combines 3D cone-beam computed tomography, 2D fluoroscopy, and digital radiography in a single system, integrating with the company's ExcelsiusGPS robotic navigation system for intraoperative imaging and robotic navigation within surgical workflows.

The CE mark, received in addition to the FDA 510(k) clearance in 2021, marks an important milestone for Globus Medical in expanding the Excelsius Ecosystem across European Union and United Kingdom markets.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.